Skip to main content

Advertisement

SpringerLink
Log in

Optimal radiotherapy for non-small-cell lung cancer: current progress and future challenges

  • Current Topics Review Article
  • Published:
General Thoracic and Cardiovascular Surgery Aims and scope Submit manuscript

Abstract

Radiotherapy has a key role in treating lung cancer. Advances in physics and computer technology have improved radiation delivery systems. With innovations in the radiation therapy of non-small-cell lung cancer (NSCLC), new strategies have emerged, such as intensity-modulated radiation therapy, stereotactic body radiation therapy, and particle therapy. Compared with previous methods, these newer technologies can deliver even higher doses precisely to the tumor while minimizing doses to normal tissues, which should lead to better tumor control with less toxicity. In patients with stage I NSCLC, stereotactic body radiation therapy is highly effective and may achieve local control and survival equivalent to that achieved with surgery. In patients with stage III NSCLC, dose escalation has been investigated using three-dimensional conformal radiation therapy, intensity-modulated radiation therapy, and particle therapy. The results from ongoing randomized trials on both patient populations are awaited. It is important to generate new hypotheses and to explore newer radiotherapy approaches to overcome NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Robertson JM, Ten Haken RK, Hazuka MB, Turrisi AT, Martel MK, Pu AT, et al. Dose escalation for non-small cell lung cancer using conformal radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:1079–1085.

    Article  PubMed  CAS  Google Scholar 

  2. Armstrong J, McGibney C. The impact of three-dimensional radiation on the treatment of non-small cell lung cancer. Radiother Oncol 2000;56:157–167.

    Article  PubMed  CAS  Google Scholar 

  3. Dosoretz DE, Katin MJ, Blitzer PH, Rubenstein JH, Galmarini DH, Garton GR, et al. Medically inoperable lung carcinoma: the role of radiation therapy. Semin Radiat Oncol 1996;6:98–104.

    Article  PubMed  Google Scholar 

  4. Gauden S, Ramsay J, Tripcony L. The curative treatment by radiotherapy alone of stage I non-small cell carcinoma of the lung. Chest 1995;108:1278–1282.

    Article  PubMed  CAS  Google Scholar 

  5. Kaskowitz L, Graham MV, Emami B, Halverson KJ, Rush C. Radiation therapy alone for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1993;27:517–523.

    Article  PubMed  CAS  Google Scholar 

  6. Martini N, Bains MS, Burt ME, Zakowski MF, McCormack P, Rusch VW, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995;109:120–129.

    Article  PubMed  CAS  Google Scholar 

  7. Morita K, Fuwa N, Suzuki Y, Nishio M, Sakai K, Tamaki Y, et al. Radical radiotherapy for medically inoperable non-small cell lung cancer in clinical stage I: a retrospective analysis of 149 patients. Radiother Oncol 1997;42:31–36.

    Article  PubMed  CAS  Google Scholar 

  8. Willers H, Wurschmidt F, Bunemann H, Heilmann HP. Highdose radiation therapy alone for inoperable non-small cell lung cancer: experience with prolonged overall treatment times. Acta Oncol 1998;37:101–105.

    Article  PubMed  CAS  Google Scholar 

  9. Grutters JP, Kessels AG, Pijls-Johannesma M, De Ruysscher D, Joore MA, Lambin P. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for nonsmall cell lung cancer: a meta-analysis. Radiother Oncol 2010;95:32–40.

    Article  PubMed  CAS  Google Scholar 

  10. Zimmermann FB, Geinitz H, Schill S, Grosu A, Schratzenstaller U, Molls M, et al. Stereotactic hypofractionated radiation therapy for stage I non-small cell lung cancer. Lung Cancer 2005;48:107–114.

    Article  PubMed  Google Scholar 

  11. Fakiris AJ, McGarry RC, Yiannoutsos CT, Papiez L, Williams M, Henderson MA, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 2009;75:677–682.

    Article  PubMed  Google Scholar 

  12. Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005;63:1427–1431.

    Article  PubMed  Google Scholar 

  13. Timmerman R. RTOG 0236: stereotactic body radiation therapy (SBRT) to treat medically inoperable early stage lung cancer patients. Int J Radiat Oncol Biol Phys 2009;75(suppl):S3.

    Article  Google Scholar 

  14. Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 2004;101:1623–1631.

    Article  PubMed  Google Scholar 

  15. Nagata Y, Hiraoka M, Shibata T, Onishi H, Kokubo M, Karasawa K, et al. A phase II trial of stereotactic body radiation therapy for operable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group (JCOG0403). Int J Radiat Oncol Biol Phys 2010;78(suppl):S27–S28.

    Article  Google Scholar 

  16. Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, et al. A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol 2008;3: 46–52.

    Article  PubMed  Google Scholar 

  17. Matsuoka H, Okada M, Sakamoto T, Tsubota N. Complications and outcomes after pulmonary resection for cancer in patients 80 to 89 years of age. Eur J Cardiothorac Surg 2005;28:380–383.

    Article  PubMed  Google Scholar 

  18. Hurkmans CW, Cuijpers JP, Lagerwaard FJ, Widder J, van der Heide UA, Schuring D, et al. Recommendations for implementing stereotactic radiotherapy in peripheral stage IA nonsmall cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study. Radiat Oncol 2009;4:1.

    Article  PubMed  Google Scholar 

  19. Perez C. A prospectiv e randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat cell carcinoma of the lung: preliminary report by the Radiation Therapy Oncology Group. Cancer 1980;45:2744–2753.

    Article  PubMed  CAS  Google Scholar 

  20. LeChevalier T. Radioth erapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991;83:417–423.

    Article  CAS  Google Scholar 

  21. ICRU. Prescribing, reco rding, reporting, photon beam therapy. Bethesda: ICRU; 1993. Report No. 50.

    Google Scholar 

  22. ICRU. Prescribing, reco rding, reporting, photon beam therapy. Supplement to ICRU Report 50. Bethesda: ICRU: 1999. Report No. 62.

    Google Scholar 

  23. Giraud P, Antoine M, Larrouy A, Milleron B, Callard P, De Rycke Y, et al. Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. Int J Radiat Oncol Biol Phys 2000;48: 1015–1024.

    Article  PubMed  CAS  Google Scholar 

  24. ICRU. Prescribing, recor ding, and reporting intensity-modulated photon-beam therapy (IMRT) (ICRU Report 83). J ICRU 2010;10(1).

  25. Sulman EP, Komaki R, Klopp AH, Cox JD, Chang JY. Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer. Radiat Oncol 2009;4:5.

    Article  PubMed  Google Scholar 

  26. Belderbos JS, Kepka L, Spring Kong FM, Martel MK, Videtic GM, Jeremic B. Report from the International Atomic Energy Agency (IAEA) consultants’ meeting on elective nodal irradiation in lung cancer: non-small-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 2008;72:335–342.

    Article  PubMed  Google Scholar 

  27. Grills IS, Yan D, Martinez AA, Vicini FA, Wong JW, Kestin LL. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys 2003;57:875–890.

    Article  PubMed  Google Scholar 

  28. Senan S, Burgers S, Samson MJ, van Klaveren RJ, Oei SS, van Sornsen de Koste J, et al. Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapy. Int J Radiat Oncol Biol Phys 2002;54:999–1006.

    Article  PubMed  Google Scholar 

  29. Rosenzweig KE, Sim SE, Mychalczak B, Braban LE, Schindelheim R, Leibel SA. Elective nodal irradiation in the treatment of non-small-cell lung cancer with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 2001;50:681–685.

    Article  PubMed  CAS  Google Scholar 

  30. Yuan S, Sun X, Li M, Yu J, Ren R, Yu Y, et al. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. Am J Clin Oncol 2007;30:239–244.

    Article  PubMed  CAS  Google Scholar 

  31. Kepka L, Bujko K, Zolciak-Siwinska A. Risk of isolated nodal failure for non-small cell lung cancer (NSCLC) treated with the elective nodal irradiation (ENI) using 3D-conformal radiotherapy (3D-CRT) techniques: a retrospective analysis. Acta Oncol 2008;47:95–103.

    Article  PubMed  Google Scholar 

  32. Bradley J. Phase I results of R TOG 0117: a phase I/II dose intensification study using 3DCRT and concurrent chemotherapy for patients with inoperable non-small cell lung cancer. J Clin Oncol 2005;24:7063A.

    Google Scholar 

  33. Schild S. Results of a phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small cell lung cancer. Int J Rad Oncol Biol Phys 2005;63: S44.

    Google Scholar 

  34. Rosenman JG, Halle JS, Socinski MA, Deschesne K, Moore DT, Johnson H, et al. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys 2002;54:348–356.

    Article  PubMed  Google Scholar 

  35. Blackstock A, Socinski MA, Bogart J, Gu L, Wang X, Green M, et al. Induction plus concurrent chemotherapy with high dose (74 Gy) 3 dimensional (3-D) thoracic radiotherapy in stage III non-small cell lung cancer. Preliminary report of CALGB 30105. J Clin Oncol 2006;24:7042.

    Article  Google Scholar 

  36. Schild SE, Bogart JA. Innovation s in the radiotherapy of nonsmall cell lung cancer. J Thorac Oncol 2006;1:85–92.

    Article  PubMed  Google Scholar 

  37. Chang JY, Zhang X, Wang X, Kang Y, Riley B, Bilton S, et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in stage I or stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006;65:1087–1096.

    Article  PubMed  Google Scholar 

  38. Pijls-Johannesma M, Grutters JP, Lambin P, Ruysscher DD. Particle therapy in lung cancer: where do we stand? Cancer Treat Rev 2008;34:259–267.

    Article  PubMed  CAS  Google Scholar 

  39. Soares HP, Kumar A, Daniels S, Swann S, Cantor A, Hozo I, et al. Evaluation of new treatments in radiation oncology: are they better than standard treatments? JAMA 2005;293: 970–978.

    Article  PubMed  CAS  Google Scholar 

  40. Komaki R, Seiferheld W, Curran W, Langer C, Lee JS, Hauser S, et al. Sequential vs. concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC): analysis of failures in a phase III study (RTOG 9410). Int J Radiat Oncol Biol Phys 2000;48(suppl): S113.

    Google Scholar 

  41. Choy H, Jain AK, Moughan J, Curran W, Whipple G, Demas WF, et al. RTOG 0017: a phase I trial of concurrent gemcitabine/carboplatin or gemcitabine/paclitaxel and radiation therapy (“ping-pong trial”) followed by adjuvant chemotherapy for patients with favorable prognosis inoperable stage IIIA/B non-small cell lung cancer. J Thorac Oncol 2009;4:80–86.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, Nagoya City University, Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan

    Satoshi Ishikura

Authors
  1. Satoshi Ishikura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Satoshi Ishikura.

Additional information

This review was submitted at the invitation of the editorial committee.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ishikura, S. Optimal radiotherapy for non-small-cell lung cancer: current progress and future challenges. Gen Thorac Cardiovasc Surg 60, 127–131 (2012). https://doi.org/10.1007/s11748-011-0832-y

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11748-011-0832-y

Key words

Search

Navigation